Victoria Colliver is a health and science journalist specializing in policy-driven coverage of infectious diseases and healthcare accessibility. Based at UC San Francisco since 2023, she translates clinical research into public-facing narratives with measurable policy impacts.
Victoria Colliver has built a 25-year career dissecting complex health systems through human-centered narratives. Her trajectory spans three distinct phases:
"These long-acting treatments are likely to be transformative for people in this population... It's exciting to see success in the population we're most worried about." - Dr. Matthew Spinelli in Colliver's March 2025 HIV therapy report
Colliver prioritizes interventions that reduce care disparities. Successful pitches highlight measurable outcomes across socioeconomic groups, like her 2025 analysis of HIV injectables' impact on unhoused populations. Propose stories examining how new treatments affect Medicaid enrollment patterns or rural clinic accessibility.
With 68% of her UCSF articles referencing pending legislation, tie medical advances to regulatory timelines. Her award-winning ACA coverage stemmed from tracking Covered California's formulary decisions. Pitch comparative analyses of state-level drug approval processes or Medicaid reimbursement frameworks for emerging therapies.
Colliver's most cited works use multi-year datasets, like her 4-year HIV therapy follow-up. Propose partnerships with institutions possessing decade-spanning patient registries, particularly in chronic disease management. Avoid one-off studies without built-in replication mechanisms.
Her POLITICO era revealed a knack for profiling unlikely collaborations, like hospital-tech startup partnerships reducing ER wait times. Pitch narratives about academic centers working with grassroots organizations, emphasizing measurable community health improvements.
While Colliver reports on drug developments, only 12% of her articles focus on pharmaceutical companies. Successful pitches center care delivery systems rather than corporate milestones. For example, her 2024 long COVID piece highlighted clinic workflow adaptations rather than antiviral trials.
Injectable Therapy Is 'Magic' for Those Who Can't Take HIV Pills
About 5% of U.S. adults are estimated to be living with long COVID-19
With the number of traffic fatalities on the rise, San Francisco is quickly becoming one of the country's most dangerous cities to navigate on foot
At PressContact, we aim to help you discover the most relevant journalists for your PR efforts. If you're looking to pitch to more journalists who write on Health, here are some other real estate journalist profiles you may find relevant: